NCT05392881Recruiting
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 22 May 2022
- Start date
- 9 Aug 2021
- Primary completion date
- 1 Aug 2031
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT05392881
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 9 Aug 2021 to the primary completion date, 1 Aug 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
- The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
- The participant is ≥ 18 years of age.
- The participant has signed an approved consent for this study (living patients only)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.